Company profile: Caribou Biosciences
1.1 - Company Overview
Company description
- Provider of CRISPR genome-editing technologies and allogeneic CAR-T cell therapies for oncology. Offers chRDNA to enhance precision and reduce off-target effects; off-the-shelf CAR-T therapies for hematologic malignancies and autoimmune diseases; and candidates CB-010 (anti-CD19 for B cell non-Hodgkin lymphoma), CB-011 (anti-BCMA for multiple myeloma), and CB-012 (anti-CLL-1 for acute myeloid leukemia).
Products and services
- Off-the-shelf CAR-T Cell Therapies: Allogeneic CAR-T cell therapies developed from healthy donor cells, designed to be readily available for treating hematologic malignancies and autoimmune diseases
- ChRDNA Technology: Custom-engineered genome-editing technology combining RNA and DNA to enhance precision and reduce off-target effects in CRISPR applications
- CB-010: Allogeneic anti-CD19 CAR-T therapy with checkpoint disruption engineered to target B cell non-Hodgkin lymphoma and reduce T cell exhaustion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Caribou Biosciences
Agritope
HQ: United States
Website
- Description: Provider of new fruit and vegetable plant varieties for the fresh produce industry, utilizing patented ethylene control technology to develop fruits and vegetables resistant to the decaying effects of ethylene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agritope company profile →
Lexent Bio
HQ: United States
Website
- Description: Provider of novel liquid biopsy technology for cancer diagnosis and treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexent Bio company profile →
Biomodal
HQ: United Kingdom
Website
- Description: Provider of DNA sequencing tools and multiomic solutions enabling combined genetic and epigenetic analysis from low-input DNA, distinguishing 5mC and 5hmC via duet multiomics solution evoC and +modC, which integrates assay and software for use with existing NGS pipelines; and modality, an analysis package for efficient, scalable 5- and 6-base genome analysis to inform genome organization and gene regulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomodal company profile →
Evonetix
HQ: United Kingdom
Website
- Description: Provider of a benchtop platform that synthesizes, assembles, and error-corrects gene-length DNA on a silicon chip with unprecedented accuracy and scale using thermal control of DNA synthesis. Offers chip technology to synthesize thousands of oligonucleotide sequences simultaneously, binary assembly, and thermal error removal for rapid, precise gene synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evonetix company profile →
Horizon Discovery
HQ: United Kingdom
Website
- Description: Provider of gene editing and gene modulation platforms and services, including the Pin-point Base Editing Platform for precise base changes, Dharmacon siRNA, shRNA, and CRISPR reagents, drug discovery screening services, pre-engineered cell lines, and Mimix cell line-derived molecular reference standards for research and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Horizon Discovery company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Caribou Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Caribou Biosciences
2.2 - Growth funds investing in similar companies to Caribou Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Caribou Biosciences
4.2 - Public trading comparable groups for Caribou Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →